6/6 Our findings suggest that lncRNAs could be promising biomarkers to guide PARPi therapy and support better treatment decisions in ovarian cancer.
There’s still much to test before this can move into the clinic, but the potential is exciting.

#OvarianCancer #HGSC #LncRNA #PARPi #Biomarker

5/6 Functionally, this lncRNA helps maintain genome stability by regulating DNA replication.
Loss of it speeds up replication, causing DNA damage + instability.
#OvarianCancer #HGSC #LncRNA #PARPi #Biomarker

4/6 Even better: it’s detectable in both tissue and plasma.
That means it could work as a minimally invasive blood-based biomarker for HRD, measurable with a simple RT-PCR test.

#OvarianCancer #HGSC #LncRNA #PARPi #Biomarker

3/6 The top hit: ENSG00000272172.1
Upregulated in HRD+ tumors Strongly correlated with HRD-score in TCGA + independent samples
Higher expression → better overall survival
#OvarianCancer #HGSC #LncRNA #PARPi #Biomarker

2/6 We asked: could long non-coding RNAs (lncRNAs) be predictive? We found in the TCGA data a panel of 29 lncRNAs linked to HRD status and drug sensitivity in HGSC tumors. #OvarianCancer #HGSC #LncRNA #PARPi #Biomarker

1/6 High-grade serous ovarian cancer (HGSC) is one of the deadliest cancers. PARP inhibitors (PARPi) help patients with homologous recombination deficiency (HRD), especially those with BRCA1/2 mutations, but current biomarkers are limited. #OvarianCancer #HGSC #LncRNA #PARPi #Biomarker

Fucking go birds